Biosimilar Specialist Henlius Takes Off. Now Comes the Hard Part

Fosun Pharma-backed company posts huge revenue jump in the second half of last year, as it boosts production and signs more global licensing deals to stay ahead of competition Key takeaways: Henlius is one of the earliest entrants to China’s young biosimilar market, giving it a first-mover advantage The company will need to quickly develop more new drugs, boost production and sign new partnerships to stay ahead in an increasingly crowded field By Richard Barbarossa Biosimilar specialist Shanghai Henlius Biotech, Inc. (HKEx: 2696) is set to ramp up production after…

Read MORE »

Online Drug Supplier 111 Finds Tonic in B2B Focus

Company adds two fulfillment centers, inks deal with cancer drug maker BeiGene, in drive to consolidate its place as premier B2B specialist Key takeaways 111 Inc.’s aggressive pursuit of partnerships with global drug makers and expansion of its regional logistics centers bodes well for its B2B business growth The company may have to further expand its consumer-focused online healthcare services if it wants to truly compete with omnichannels like Alibaba Health and JD Health. By Richard Barbarossa Online drug and healthcare services provider 111 Inc. (Nasdaq: YI) is rapidly building…

Read MORE »

No Beauty in Cosmetic Surgery Specialist So-Young’s Latest Earnings

Company posts strong user growth in last year’s fourth quarter, but revenue expanded far slower and profits plunged due to rising costs Key Takeaways: So-Young is gaining traction as a leading marketplace for information and services from China’s cosmetic surgery sector The company will face difficulty monetizing its business due to the industry’s fragmented state, with meaningful consolidation still likely several years away   By Doug Young Cosmetic surgery specialist So-Young International Inc. (Nasdaq: SY) has just reported its latest quarterly results, and – puns aside – they weren’t pretty. That’s…

Read MORE »

Burning Rock Builds Up Hospital Partner Pipeline as Losses Mount

Precision cancer diagnostics developer’s fourth-quarter revenue grew 50%, as two more of its key products moved closer to commercialization By Richard Barbarossa Burning Rock Biotech Ltd. (NASDAQ: BNR) posted a widening quarterly loss in the fourth quarter, but remained upbeat about its prospects due to a strong pipeline of new business from its core hospital clients setting up in-house labs for its cancer test kits. While its near-term profit outlook remains elusive, the company provided another positive signal with word that it has initiated preliminary talks with China’s drug regulator,…

Read MORE »

Kintor Pharma Wins U.S. Nod for Phase III Trial of Covid Drug

Cancer drug specialist hopes its novel drug Proxalutamide can be approved for treatment of mild to moderate cases of novel coronavirus infections By Richard Barbarossa Cancer drug maker Kintor Pharmaceutical Ltd. (HKEx: 9939) has become China’s first company approved for Phase III clinical trials for its Covid 19 drug in the U.S., moving it closer to launching its first product for commercial sale. The U.S. Food and Drug Administration’s (FDA) approval for trials of the company’s Proxalutamide drug for treatment of mild to moderate Covid 19 symptoms in males is…

Read MORE »